Accessibility Menu
Hikma Pharmaceuticals Plc logo

Hikma Pharmaceuticals Plc(OTC) HKMPF

Current Price$20.37
Market Cap$4.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+194%
5 Year-31%
1 Year-23%
1 Month+6%
Hikma Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeUSD 20.372026-07-20
Hikma Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.19%USD 21.262026-07-10
1 month+5.6%USD 19.292026-06-18
3 month+8.84%USD 18.722026-04-17
Year to date+0.05%USD 20.362025-12-29
1 year-23.29%USD 26.562025-07-15
3 year-14.06%USD 23.702023-07-21
5 year-31.2%USD 29.612021-07-12
Since inception+193.86%USD 6.932007-06-28

Hikma Pharmaceuticals Plc Financials at a Glance

Market Cap

$4.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.49B

Net Income (TTM)

$761.99M

EPS (TTM)

$1.82

P/E Ratio

11.19

Dividend

$0.84

Beta (Volatility)

0.29 (Low)

Price

$20.37

Volume

450

Open

$20.37

Previous Close

$20.37

Daily Range

$20.37 - $20.37

52-Week Range

$16.34 - $27.96

Estimated Earnings Date

Aug 6, 2026

HKMPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC is a global pharmaceutical firm engaged in the development, manufacturing, commercialization, and distribution of a wide array of medications. The company operates through three core segments: Injectables, Generics, and Branded products, addressing diverse medical needs across various therapeutic areas.

Products and Services
  • Injectables: Generic injectable medications primarily for hospitals
  • Generics: Oral and non-injectable generic drugs for the retail market
  • Branded: Proprietary generics and in-licensed pharmaceuticals for consumers
Growth Outlook
  • Revenue increased to $1.7 billion in Q4 2025, reflecting strong demand
  • Net income rose to $165 million in Q4 2025, showcasing profitability
  • Operating income margin improved to 18% in Q4 2025, indicating operational efficiency
Financial Highlights
  • Trailing twelve months (TTM) revenue of $6.5 billion, demonstrating consistent growth
  • Dividend yield of 3.86%, providing attractive returns to shareholders
  • Net profit margin of 12% TTM, reflecting effective cost management
Hikma Pharmaceuticals PLC has established itself as a key player in the pharmaceutical industry, with a diverse product portfolio that meets various healthcare needs. The company's focus on injectables and generics positions it well for future growth, particularly in markets with increasing demand for affordable medications. Recent financial performance indicates a robust upward trend, with significant revenue and profit growth, making it an appealing option for potential investors. The company's commitment to operational efficiency and cost management further enhances its attractiveness in the competitive pharmaceutical landscape.
AI Generated • Jul 10, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,400

CEO

Riad Mishlawi

Website

www.hikma.com

Headquarters

London, GL W1H 6AZ, GB

HKMPF Financials

Key Financial Metrics (TTM)

Gross Margin

41.35%

Operating Margin

16.81%

Net Income Margin

12.00%

Return on Equity

15.83%

Return on Capital

13.82%

Return on Assets

7.10%

Earnings Yield

8.94%

Dividend Yield

4.12%

Payout Ratio

45.16%

Stock Overview

Market Cap

$4.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

209.43M

Volume

450

Avg. Volume

296.258

Financials (TTM)

Gross Profit

$2.81B

Operating Income

$1.18B

EBITDA

$1.67B

Operating Cash Flow

$954.22M

Capital Expenditure

-$360.54M

Free Cash Flow

$593.68M

Cash & ST Invst.

$354.57M

Total Debt

$1.60B

Hikma Pharmaceuticals Plc Performance Analysis

Hikma Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,517,000,000-1.4%
20232023-12-31USD 2,875,000,00014.2%
20242024-12-31USD 3,127,000,0008.8%
20252025-12-31USD 3,349,000,0007.1%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-308.4%
Q42024-12-31-0.7%
Q22025-06-306.4%
Q42025-12-312.6%
Hikma Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.84-53.8%
20232023-12-31USD 0.852.2%
20242024-12-31USD 1.6188.0%
20252025-12-31USD 1.8112.4%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30274.1%
Q42024-12-31-40.6%
Q22025-06-3078.3%
Q42025-12-31-30.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.70B

+17.5%

Gross Profit

$674.05M

-2.6%

Gross Margin

39.62%

N/A

Market Cap

$4.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$453.83K

N/A

Employees

9,400

N/A

Net Income

$164.99M

+179.6%

EBITDA

$411.47M

+19.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$354.57M

+54.8%

Total Debt

$1.60B

+34.7%

Accounts Receivable

$1.08B

+37.0%

Inventory

$1.11B

+24.3%

Long Term Debt

$1.49B

+44.7%

Short Term Debt

$114.00M

-29.2%

Return on Assets

7.10%

N/A

Return on Invested Capital

13.38%

N/A

Free Cash Flow

$101.68M

-66.2%

Operating Cash Flow

$229.22M

-40.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FLMNFFielmann AG
$50.75+0.00%
DNPUFSumitomo Pharma Co., Ltd.
$8.41+0.00%
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited
$2.34+0.00%
OPHLFOno Pharmaceutical Co., Ltd.
$14.61+9.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About HKMPF

What is the current price of Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc is trading at $20.37 per share.

What is the 52-week range for Hikma Pharmaceuticals Plc?

Over the past 52 weeks, Hikma Pharmaceuticals Plc has traded between $16.34 and $27.96.

How much debt does Hikma Pharmaceuticals Plc have?

As of the most recent reporting period, Hikma Pharmaceuticals Plc reported total debt of $1.60B.

How much cash does Hikma Pharmaceuticals Plc have on hand?

Hikma Pharmaceuticals Plc reported $328.00M in cash and cash equivalents in its most recent financial results.

What is Hikma Pharmaceuticals Plc’s dividend yield?

Hikma Pharmaceuticals Plc currently has a dividend yield of 4.12%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services